LSL Pharma Group (TSXV:LSL) EV-to-EBIT : -10.43 (As of May. 26, 2024)

LSL Pharma Group EV-to-EBIT Chart

LSL Pharma Group Quarterly Data
	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial							-	-8.18	-4.49	-5.74	-8.15

Competitive Comparison of LSL Pharma Group's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LSL Pharma Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LSL Pharma Group's EV-to-EBIT falls into.

LSL Pharma Group EV-to-EBIT Calculation

LSL Pharma Group's EV-to-EBIT for today is calculated as:

LSL Pharma Group's current Enterprise Value is C$70.26 Mil.
LSL Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group  (TSXV:LSL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

LSL Pharma Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

LSL Pharma Group's Enterprise Value for the quarter that ended in Dec. 2023 was C$56.24 Mil.
LSL Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of LSL Pharma Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

LSL Pharma Group (TSXV:LSL) Business Description